SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-022891
Filing Date
2020-05-07
Accepted
2020-05-07 16:21:49
Documents
61
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sage-10q_20200331.htm   iXBRL 10-Q 2455234
2 EX-31.1 sage-ex311_6.htm EX-31.1 9344
3 EX-31.2 sage-ex312_7.htm EX-31.2 9280
4 EX-32.1 sage-ex321_8.htm EX-32.1 8643
5 GRAPHIC ghb4zssfgsud000001.jpg GRAPHIC 31368
  Complete submission text file 0001564590-20-022891.txt   8041454

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA sage-20200331.xsd EX-101.SCH 50274
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sage-20200331_cal.xml EX-101.CAL 40966
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sage-20200331_def.xml EX-101.DEF 201853
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20200331_lab.xml EX-101.LAB 395650
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20200331_pre.xml EX-101.PRE 319773
15 EXTRACTED XBRL INSTANCE DOCUMENT sage-10q_20200331_htm.xml XML 1461440
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36544 | Film No.: 20856788
SIC: 2834 Pharmaceutical Preparations